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MaBACKGROUND There are limited long-term, single-cohort, follow-up studies available about patients after the Fontan
operation.
OBJECTIVES This study sought to determine the long-term outcome of all patients who had a Fontan operation at the
Mayo Clinic.
METHODS Records of all patients who had a modiﬁed Fontan operation between 1973 and 2012 were reviewed.
A follow-up questionnaire was mailed to all patients alive at the time of the study.
RESULTS Overall, 10-, 20-, and 30-year survival for 1,052 patients was 74%, 61%, and 43%, respectively. Factors
associated with decreased overall or late survival in multivariate analysis included pre-operative diuretic use, longer car-
diopulmonary bypass time, operation prior to 1991, atrioventricular valve (AVV) replacement at the time of Fontan oper-
ation, elevated post-bypass Fontan (>20 mm Hg) or left atrial (>13 mm Hg) pressures, prolonged chest tube drainage
(>21 days), post-operative ventricular arrhythmias, renal insufﬁciency, and development of protein-losing enteropathy
(PLE). Pre-operative and intraoperative sinus rhythm were associated with improved survival. Long-term survival was
similar for patients regardless of ventricular morphology. The most common reoperations were pacemaker insertion/
revision in 212 patients (20%), Fontan revision/conversion in 117 patients (11%), and AVV repair/replacement in 66 patients
(5%). Clinically signiﬁcant late atrial or ventricular arrhythmias occurred in 468 patients (44%). Ninety-ﬁve patients (9%)
developed PLE, and 5-, 10-, and 20-year survival after diagnosis of PLE was 50%, 35%, and 19%, respectively.
CONCLUSIONS As the surgical techniques for the Fontan operation have changed over the last 40 years, survival has
improved. However, development of PLE and arrhythmias and the need for reoperation during long-term follow-up pose
signiﬁcant management challenges. (J Am Coll Cardiol 2015;66:1700–10) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
AVV = atrioventricular valve
LA = left atrial
PAP = pulmonary artery
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1701Fontan procedure have been recognized, including
premature death, ventricular failure, thromboem-
bolic disease, arrhythmia, liver disease, and protein-
losing enteropathy (PLE) (8–14). In this study, we
sought to determine long-term outcomes for all pa-
tients who had a Fontan operation at our institution.SEE PAGE 1711
pressure
PLE = protein-losing
enteropathy
SVEDP = systemic ventricular
end-diastolic pressureMETHODS
In this institutional review board–approved, single-
center, retrospective study, we reviewed the records
of all patients (n ¼ 1,052) who had their initial Fontan
operation at the Mayo Clinic between October 1973
and June 2012 and who provided informed consent to
participate in the study. Information regarding de-
mographic, anatomic, pre-operative, operative, and
post-operative variables, and Mayo follow-up was
abstracted into a secure electronic database. Many of
the patients had their follow-up care at other in-
stitutions. Any available correspondence regarding
echocardiogram, cardiac catheterization, electrocar-
diogram, Holter/event monitor, laboratory tests, liver
imaging, or surgical/procedural data was entered into
the patient database.
A medical questionnaire was mailed to all patients
not known to be dead at the initiation of the study.
Nonresponders received second and third question-
naires, and if these were not returned or completed,
an attempt was made to contact the patients by
telephone. Quality-of-life surveys from patients
rated their current health status on a scale of 1 to 4
(1 ¼ excellent, 2 ¼ good, 3 ¼ fair, and 4 ¼ poor). Data
regarding death were updated using correspondence
from physicians and patients/family members, chart
review, and the Social Security Death Index. For
the remaining patients, data curves were censured
using the date of last available follow-up or date of
transplant.
PLE was diagnosed based on documentation of
enteric loss of alpha-1-antitrypsin or the presence of
low serum total protein/albumin in addition to per-
sistent or intermittent edema. Patients were excluded
from subsequent PLE analysis if the timing of diagnosis
was not known. Clinically signiﬁcant arrhythmia was
deﬁned as the need for antiarrhythmic drug therapy
(excluding digoxin), pacemaker placement, or elec-
trical/pharmacological cardioversion. Patients with
arrhythmias prior to the Fontan procedure were
excluded from any analysis of post-operative ar-
rhythmias. Cirrhosis was diagnosed based on liver bi-
opsy/autopsy or characteristic ﬁndings on computed
tomography, cardiac magnetic resonance imaging,
magnetic resonance elastography, or ultrasound inconjunction with clinical diagnosis by a
gastroenterologist. Patients with isolated liver
function or ultrasound abnormalities were not
considered to have proven cirrhosis.
Variables used in the Cox regression anal-
ysis were initially analyzed as continuous
variables, and then discrete cutoffs were
selected based on the hazard ratios. The cut-
offs for discrete variables used in univariate/
multivariate analyses were deﬁned as follows:
pre-operative pulmonary artery pressure
(PAP) (>17 mmHg), pre-operative systemic ventricular
end-diastolic pressure (>12 mm Hg), pre-operative
pulmonary arteriolar resistance (>3 U  m2), post-
bypass left atrial (LA) pressure (>13 mm Hg), post-
bypass Fontan pressure (>20 mm Hg), and prolonged
chest tube duration ($21 days).
STATISTICAL ANALYSIS. Separate analyses were
performed using either the date of the Fontan opera-
tion as time 0 (“overall survival”) or 30 days after the
operation as time 0 (“late survival”). All deaths,
regardless of cause, after the Fontan operation were
considered in the survival analysis. Descriptive
statistics for categorical variables were reported as
frequency and percentage, and continuous variables
were reported as mean  SD or median (range) as
appropriate. Time to PLE was compared between
Fontan type groups using analysis of variance. Kaplan-
Meier curves were derived to calculate 10-, 20-, and
30-year survival statistics. Cox regression models
were used to determine univariate and multivariate
predictors of survival and other long-term outcomes.
The multivariable model considered signiﬁcant uni-
variate variables (p < 0.05) with model selection using
the stepwise method. All statistical tests were 2-sided
with the alpha level set at 0.05 for statistical signiﬁ-
cance. SAS version 9.3 (SAS Institute, Inc., Cary, North
Carolina) was used for the analysis. The set of variables
evaluated for association of survival and long-term
outcomes and results of univariate Cox regression an-
alyses are listed in Online Tables 1 to 4.
RESULTS
Between 1973 and 2012, 1,052 patients had an initial
Fontan operation at the Mayo Clinic (Table 1). At last
follow-up, 426 patients (40%) were known to be
dead. Of the 626 patients known to be alive,
transplant-free survival was veriﬁed in 427 patients
(68%) with follow-up information within 5 years of
the study termination date. The mean age at initial
Fontan procedure was 9.4  7.5 years (median:
7 years; range: 7 months to 53 years). Mean follow-up
after the Fontan operation was 15.3  9.3 years
TABLE 1 Patient Demographics (N ¼ 1,052)
Male 637 (61)
Type of Fontan operation
Atriopulmonary connection 616 (59)
Lateral tunnel 262 (25)
Extracardiac conduit 120 (11)
Other 54 (5)
Pre-operative anatomy
Tricuspid atresia 273 (26)
Double inlet left ventricle 271 (26)
Heterotaxy 135 (13)
Pulmonary atresia/intact septum 35 (3)
Hypoplastic left heart syndrome 24 (2)
Other 314 (30)
Values are n (%).
FIGURE 1 Overall Survival
100
80
60
40
20
0
%
100
80
60
40
20
(%
)
0
0
Follo
0 10
Follo
O
Overall s
Surgical era < = 1990
2001+
< = 1990
1991—2000
2001+
775
191
86
A
B
1052 650
Over time, overall survival after the Fontan operation predictably decre
Pundi et al. J A C C V O L . 6 6 , N O . 1 5 , 2 0 1 5
Long-Term Follow-Up After the Fontan Operation O C T O B E R 1 3 , 2 0 1 5 : 1 7 0 0 – 1 0
1702(median: 15.1 years; range: 34 days to 37 years). The
oldest survivor after the Fontan operation was
67 years of age (Fontan at age 39 years). Of the 723
follow-up questionnaires mailed out, 305 (42%) were
returned.
SURVIVAL. Overall, 10-, 20-, and 30-year survival
after the Fontan operation was 74%, 61%, and 43%,
respectively (Figure 1A). Overall survival by surgical
era, type of Fontan procedure, and pre-operative
anatomy are depicted in Figures 1B, 2, and 3, respec-
tively. Kaplan-Meier estimates of overall survival are
listed in Table 2, and factors associated with
decreased overall survival in multivariate analysis are
in Table 3. When only pre-operative variables were
considered, factors associated with decreased overall
survival in multivariate analysis included operation5 10
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ased (A) but improved signiﬁcantly in later surgical eras (B).
FIGURE 2 Overall Survival by Type of Fontan Procedure
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The type of procedure performed greatly impacted survival; patients who had their Fontan with an extracardiac conduit had signiﬁcantly less
mortality. Ap ¼ atriopulmonary.
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1703prior to 1991, use of pre-operative diuretics, asplenia,
and lack of pre-operative sinus rhythm. Fenestration
was associated with improved overall survival only
on univariate analysis. However, only 86 patients
(8%) underwent fenestration at the time of their
initial Fontan procedure (most of which were per-
formed after 1995). Ventricular morphology did not
impact overall survival.FIGURE 3 Overall Survival by Pre-Operative Anatomy
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Patients with heterotaxy had the lowest overall survival after Fontan. L
septum. HLHS ¼ hypoplastic left heart syndrome.The 10-, 20-, and 30-year survival for the 932
patients who were alive 30 days after the Fontan
operation was 83%, 68%, and 48% respectively.
Kaplan-Meier estimates of late survival are listed in
Table 4. Factors associated with decreased late sur-
vival in multivariate analysis are listed in Table 5.
When only pre-operative variables were considered,
factors associated with decreased late survival5 10
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TABLE 2 Overall Survival Estimate Post–Fontan Operation
N
10-Yr
Survival, %
20-Yr
Survival, %
30-Yr
Survival, %
Overall 1,052 74 61 43
Operative era
1973–1990 775 69 57 39
1991–2000 191 89 74
2001 onward 86 95
Age at Fontan
<2 yrs 24 79 62
2–4 yrs 200 78 72 59
4–16 yrs 647 74 61 49
>16 yrs 181 71 54 28
Pulmonary vein anatomy
Normal 931 76 63 44
Abnormal 121 61 46 28
Inferior vena cava
Normal 976 75 62 44
Interrupted 76 61 53
Bidirectional Glenn
Absent 893 71 59 41
Present 159 94 68
Pre-operative sinus
rhythm
Absent 64 55 33 15
Present 988 75 63 44
Pre-operative PAP
Normal (#17 mm Hg) 451 81 68 45
Abnormal (>17 mm Hg) 476 68 54 40
Pre-operative pulmonary
arteriolar resistance
Normal (#3 mm Hg) 619 75 60 43
Abnormal (>3 mm Hg) 63 59 50
Pre-operative SVEDP
Normal (#12 mm Hg) 608 79 66 48
Abnormal (>12 mm Hg) 355 67 54 36
Type of Fontan
connection
Atriopulmonary 616 70 58 41
Intra-atrial tunnel 262 75 63 35
Extracardiac conduit 120 94 60 60
Other 54 74 63 42
Fenestration
Absent 966 73 60 42
Present 86 85 73
AVV replacement at the
time of Fontan
No 1,029 75 62 43
Yes 23 25 8
Post-bypass Fontan
pressure
#20 mm Hg 887 79 66 48
>20 mm Hg 117 40 32 11
AVV ¼ atrioventricular valve; PAP ¼ pulmonary artery pressure; SVEDP ¼ systemic
ventricular end-diastolic pressure.
TABLE 3 Overall Survival Post–Fontan Operation
HR 95% CI p Value
Surgical era 1991–2000* 0.52 0.36-0.75 <0.001
Surgical era 2001 onward* 0.28 0.09-0.87 0.03
Intraoperative sinus rhythm 0.70 0.52-0.95 0.02
Pre-operative use of diuretics 1.86 1.46-2.37 <0.001
Post-operative LA pressure >13 mm Hg 1.84 1.40-2.42 <0.001
Post-operative Fontan pressure
>20 mm Hg
2.14 1.63-2.81 <0.001
Longer bypass time† 1.14 1.07-1.22 <0.001
*Compared with the surgical era from 1973 through 1990. †For every 30-min
increase in overall bypass time.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LA ¼ left atrial.
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diuretics or amiodarone, interrupted inferior vena
cava (heterotaxy), and lack of pre-operative sinus
rhythm.EARLY REOPERATIONS AND COMPLICATIONS. A
total of 177 of 1,052 patients (17%) had at least 1 early
reoperation after their Fontan operation. The 3 most
common indications for reoperation were bleeding
(n ¼ 74 [42%]), wound debridement (n ¼ 38 [21%]),
and placement of a permanent pacemaker (n ¼ 35
[20%]). There were 21 patients who had early Fontan
takedown (<30 days after Fontan operation). Of
these, 12 patients (57%) died during long-term follow-
up (9 [43%] died within 30 days of takedown). The
incidence of atrial arrhythmias (n ¼ 224) and ven-
tricular arrhythmias (n ¼ 86) prior to hospital
discharge was 21% and 8%, respectively.
LONG-TERM FOLLOW-UP. Of the 426 patients known
to be deceased, cause of death was known for 281
patients (66%). A total of 234 of 281 deaths (83%) were
from a primary cardiac cause; however, the cause of
death was multifactorial in many patients. Contrib-
uting factors in the reported cause of death for 281
patients included respiratory failure (n ¼ 101 [36%]),
renal insufﬁciency (n ¼ 85 [30%]), sudden death or
arrhythmia (n ¼ 52 [19%]), bleeding complications or
cardiac tamponade (n ¼ 50 [18%]), disseminated
intravascular coagulopathy/sepsis (n ¼ 48 [17%]), PLE
(n ¼ 31 [11%]), and hepatic insufﬁciency (n ¼ 29
[10%]). Four patients died from malignancies: 2 with
hepatocellular carcinoma, 1 with metastatic cervical
cancer, and 1 with multiple myeloma.
The 10-, 20-, and 30-year freedom from death or
cardiac transplant was 73%, 59%, and 40%, respec-
tively. Factors associated with decreased survival or
transplant in multivariate analysis included elevated
pre-operative PAP (>17 mm Hg), asplenia, use of pre-
operative diuretics, operation prior to 1991, longer
bypass time, absence of intraoperative sinus rhythm,
and elevated post-bypass Fontan (>20 mm Hg) or LA
(>13 mm Hg) pressures (Table 6). Thirty-eight patients
in the cohort had heart transplants (mean age at
transplant 24.0 11.8 years), with 24 of 38 (63%) known
TABLE 4 Late Survival* Post–Fontan Operation
N
10-Yr
Survival, %
20-Yr
Survival, %
30-Yr
Survival, %
Overall 932 83 68 48
Operative era
1973–1990 676 79 65 45
1991–2000 176 95 79
2001 onward 80 98
Age at Fontan
<2 yrs 20 95 74
2–4 yrs 175 88 80 67
5–16 yrs 569 83 68 50
>16 yrs 168 76 58 30
Bidirectional Glenn
Absent 780 81 67 47
Present 152 96 70
Pre-operative sinus rhythm
Absent 56 62 37 16
Present 876 84 70 50
Pre-operative PAP
Normal (#15 mm Hg) 413 87 73 49
Abnormal (>15 mm Hg) 406 79 63 47
Pre-operative SVEDP
Normal (#12 mm Hg) 551 86 72 52
Abnormal (>12 mm Hg) 302 79 63 43
Type of Fontan
Atriopulmonary 539 80 65 46
Intra-atrial tunnel 231 84 70 39
Extracardiac conduit 111 97 62 62
Other 51 78 67 45
AVV replacement at time
of Fontan
No 916 84 69 48
Yes 16 36 12
Intraoperative sinus rhythm
Absent 89 66 42 29
Present 843 85 71 49
Post-bypass Fontan
pressure
#20 mm Hg 819 85 70 51
>20 mm Hg 76 62 50 17
Chest tube duration
1–5 days 100 85 70 52
6–10 days 325 89 76 61
11–15 days 229 87 72 43
16–20 days 125 77 69 58
>21 days 145 68 46 23
Post-operative chylous
effusions
Absent 877 83 69 48
Present 55 73 55 44
Post-operative ventricular
arrhythmias
Absent 883 84 69 49
Present 49 61 46 28
Continued in the next column
TABLE 4 Continued
N
10-Yr
Survival, %
20-Yr
Survival, %
30-Yr
Survival, %
Post-operative atrial
arrhythmias
Absent 735 84 70 52
Present 197 77 61 27
Post-operative low
cardiac output
(pressors >3 days)
Absent 535 87 73 52
Present 397 77 62 34
Post-operative renal
insufﬁciency
Absent 858 85 71 50
Present 74 53 37 26
Reoperation <30 days
after Fontan
Absent 790 85 70 50
Present 142 72 56 36
*>30 days.
Abbreviations as in Table 2.
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1705to be alive post-transplant (mean follow-up 10.4  6.9
years).
Among the 932 patients who survived at least 30 days
after the initial Fontan operation, the 10-, 20-, and 30-yearfreedom from death or reoperation was 69%, 50%, and
33%, respectively. Factors associated with decreased sur-
vival or reoperation in multivariate analysis included
asplenia, use of pre-operative diuretics, elevated pre-
operative PAP (>17 mm Hg), atriopulmonary type of Fon-
tan connection, atrioventricular valve (AVV) replacement
at the time of Fontan procedure, intraoperative rhythm
other than sinus, longer bypass time, and elevated post-
bypass Fontan pressure (>20 mm Hg) (Table 7). A prior
bidirectional Glenn procedure was associated with
improved survival and freedom from reoperation.
Most patients had their long-term follow-up
at other medical institutions. The most common
late reoperations were pacemaker insertion/revision
(n ¼ 212 [23%]), Fontan revision/conversion (n ¼ 117
[13%]), and AVV repair/replacement (n ¼ 66 [7%]).
Implantable cardioverter-deﬁbrillators were placed in
14 patients (2%) during long-term follow-up. At least
71 of 117 patients (61%) undergoing Fontan conver-
sion/revision had a prior diagnosis of arrhythmia at a
mean duration of 6.3  5.6 years prior to their oper-
ation. Of these 117 patients, 10 (9%) died within 30
days of their Fontan conversion/revision. During
long-term follow-up, 37 of 117 patients (32%) died at a
mean duration of 5.2  5.7 years (median 2.7 years)
after reoperation. There were 17 patients who had late
Fontan takedown; of these, 12 patients (71%) died
during long-term follow-up (7 [41%] within 30 days of
Fontan takedown).
Freedom from PLE at 10, 20, and 30 years after the
Fontan procedure was 92%, 89%, and 83%, respec-
tively. A total of 95 patients were diagnosed with PLE,
TABLE 5 Late Survival Post–Fontan Operation
HR 95% CI p Value
Pre-operative sinus rhythm 0.38 0.26-0.57 <0.001
AVV replacement at the time of Fontan 4.02 2.07-7.80 <0.001
Post-operative LA pressure >13 mm Hg 2.05 1.48-2.82 <0.001
Post-operative ventricular arrhythmias 1.79 1.18-2.72 0.006
Post-operative renal insufﬁciency 2.49 1.74-3.58 <0.001
Post-operative chest tube duration $21 days 1.15 1.05-1.26 0.003
PLE 1.97 1.48-2.63 <0.001
PLE ¼ protein-losing enteropathy; other abbreviations as in Tables 2 and 3.
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nosis. For these 88 patients, mean age at Fontan was
11.2  8 years and mean interval from Fontan to
diagnosis of PLE was 8.1  7.9 years (median: 5 years;
range: 2 months to 32 years). Fifty-one of 88 patients
with PLE (58%) had a date of diagnosis prior to 1995.
Fenestration at the time of Fontan procedure was
performed in 4 patients; 8 patients had late fenes-
tration as an attempted therapy for PLE. There was no
signiﬁcant difference in mean duration to onset of
PLE by type of Fontan operation. Factors associated
with development of PLE in multivariate analysis are
listed in Table 8.
Overall mortality in the PLE cohort was 72% (63
of 88) during 7.0  7.4 years of follow-up. Cause of
death was known for 36 of 88 patients: chronic
heart failure in 13, sepsis/multiorgan failure in
another 13, and other PLE-related complications in
the remaining 10. Survival at 5, 10, and 20 years
after PLE diagnosis was 50%, 35%, and 19%, res-
pectively (Central Illustration).
There were 996 of 1,052 patients (95%) who did not
have a known pre-operative arrhythmia; they were
included in arrhythmia analyses. For these patients,
the overall freedom from post-operative arrhythmias
at 10, 20, and 30 years after the Fontan operation was
71%, 42%, and 24%, respectively. New arrhythmias
were diagnosed more than 30 days after the Fontan
operation in 412 of 996 patients (41%), with some
patients having multiple arrhythmias. Late arrhyth-
mias in these 412 patients included atrial ﬂutter
(n ¼ 304 [74%]), atrial ﬁbrillation (n ¼ 161 [39%]),
atrial tachycardia (n ¼ 108 [26%]), re-entrant supra-
ventricular tachycardia (n ¼ 37 [9%]), and ventricular
tachycardia (n ¼ 40 [10%]).
A total of 195 patients had available liver imaging
or biopsy/pathology data and of these, 40 patients
(21%) were diagnosed with cirrhosis at a mean dura-
tion of 23.3  6.3 years from the Fontan procedure;
their average age at the time of Fontan operation
was 9.6  9.2 years. Five patients were diagnosed
with hepatocellular carcinoma at a mean duration of20  2.9 years after the Fontan operation (2 patients
died during long-term follow-up).
Patient rating of their current health and physical
status on the surveys returned are shown in the
Central Illustration and Figure 4.
DISCUSSION
We present the largest long-term follow-up study
from a single institution for patients after the Fontan
operation.
MORTALITY, TRANSPLANT, AND REOPERATION. As
surgical techniques and management of patients
after the Fontan operation have improved over the last
40 years, a number of investigators have reported
improvement in early and intermediate-term survival
(9,11,15). In our cohort, early mortality after Fontan
operation was 13% in the surgical era prior to 1991
but decreased to 7.8% from 1991 to 2000 and 6.9% in
the era following 2000. This increase in patient sur-
vival has been attributed tomultiple factors, including
better patient selection and improvement in operative
techniques and post-operative patient management.
Indeed, studies from the Mayo Clinic—based on our
early cohort—contributed to the development of more
appropriate selection criteria (8,10). Compared with a
similar cohort of patients having the Fontan opera-
tion at Boston Children’s Hospital (median age
7.9 years), there was a comparable high incidence of
early and late mortality after the initial Fontan
operation (12). However, unlike the Boston study, in
which there was signiﬁcant attrition in late follow-up
data, our 20-year data were based on 35% of the pa-
tients in our cohort. Many of the factors associated
with long-term mortality or transplant in the Boston
study (PLE, diuretic therapy, higher Fontan pressure)
were consistent with our study’s results.
Recent studies from the Children’s Hospital of
Philadelphia (15), the Australia/New Zealand registry
(11,16), and the University of Alabama at Birmingham
(9) noted that early and late survival after Fontan
operation was excellent, with no increase in late mor-
tality. However, these results are based on a more
recent surgical era than patients in our series, and the
Fontan connections were primarily lateral tunnel or
extracardiac Fontan connections involving younger
patients with a higher proportion of fenestrations.
Additionally, the survival data at 20 years and beyond
in these studies were based on a very small number
of patients. The long-term survival of patients with
lateral tunnel Fontan connections was poor in our
study, likely due to several reasons: 1) many of the
earlier “lateral tunnel” operations were performed
in patients with heterotaxy syndromes, for which
TABLE 6 Risk of Death or Cardiac Transplant
HR 95% CI p Value
Surgical era 1991–2000* 0.63 0.44-0.90 0.01
Surgical era 2001 onward* 0.12 0.02-0.84 0.03
Intraoperative sinus rhythm 0.64 0.47-0.88 0.005
Pre-operative mean catheter PAP
>17 mm Hg
1.42 1.15-1.77 0.001
Asplenia 1.55 1.07-2.25 0.02
Pre-operative use of diuretics 1.58 1.22-2.04 <0.001
Post-operative Fontan pressure
>20 mm Hg
2.29 1.72-3.05 <0.001
Post-operative LA pressure
>13 mm Hg
1.85 1.39-2.47 <0.001
Longer bypass time† 1.12 1.05-1.20 0.001
*Compared with the surgical era from 1973 through 1990. †For every 30-min
increase in overall bypass time.
Abbreviations as in Tables 2 and 3.
TABLE 7 Risk of Death or Reoperation
HR 95% CI p Value
Bidirectional Glenn prior to Fontan 0.41 0.24-0.70 0.001
Intraoperative sinus rhythm 0.69 0.52-0.94 0.02
Pre-operative mean catheter PAP >17 mm Hg 1.43 1.17-1.76 <0.001
Asplenia 1.81 1.23-2.64 0.002
Pre-operative use of diuretics 1.77 1.39-2.26 <0.001
Atriopulmonary Fontan connection 1.48 1.16-1.88 0.002
AVV replacement at the time of Fontan 2.42 1.39-4.22 0.002
Post-operative Fontan pressure >20 mm Hg 3.16 2.45-4.07 <0.001
Longer bypass time* 1.08 1.009-1.16 0.03
*For every 30-min increase in overall bypass time.
Abbreviations as in Tables 2 and 3.
TABLE 8 Risk of Developing PLE Post–Fontan Operation
Variable HR 95% CI p Value
Pre-operative catheter mean
PAP pressure >17 mm Hg
1.82 1.14-2.91 0.01
Post-operative LA pressure >13 mm Hg 3.10 1.70-5.66 <0.001
Late arrhythmia (as time-dependent
covariate)
1.81 1.07-3.06 0.03
Abbreviations as in Tables 2, and 3.
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1707intra-atrial conduits were used; and 2) others incorpo-
rated a variable amount of native atrial tissue into
the surgical repair, making them susceptible to some
of the same long-term complications as operations in
patients with atriopulmonary connections. Addition-
ally, ventricular morphology did not inﬂuence overall
survival in this study, presumably because a majority
of the right ventricular morphology patients in this
study did not have hypoplastic left heart syndrome
(therefore, therewasnoneed for aNorwoodoperation).
The timing of Fontan conversion, or listing for
cardiac transplant, in a patient with a long-standing
atriopulmonary Fontan connection is not always
straightforward. In this study, we noted that the <30-
day mortality with Fontan conversion/revision was
9%. Studies from multiple institutions (17–19) have
identiﬁed risk factors for poor outcome with Fontan
conversion, such as PLE, systemic right ventricular/
intermediate ventricular morphology, signiﬁcant
AVV regurgitation, older age (>27 years), elevated
systemic ventricular end-diastolic pressure, renal
dysfunction, and cirrhosis. However, either concom-
itant arrhythmia operation or concomitant surgery for
Fontan obstruction is associated with better overall
outcome. The Boston Children’s group evaluated the
outcomes of failing Fontan patients listed for trans-
plant and noted decreased survival in patients with
preserved ventricular function compared with those
with impaired ventricular function (20). This was
attributed to the challenges of determining the ideal
timing of cardiac transplant in patients with pre-
served ventricular function because it has been
shown that long-term survival is reasonable in pa-
tients with PLE despite increased early post-operative
mortality after transplant (21,22). However, in the
older atriopulmonary Fontan patients who do notclearly meet criteria for a low-risk Fontan conversion
or listing for transplant, management decisions need
to be made on an individual basis after careful
consideration of associated risks and beneﬁts.
In other large single-center studies, approximately
2% of patients required late cardiac transplant, and
there has been limited long-term follow-up (11,12). In
our cohort, 38 patients (3.6%) had heart transplants
(mean age at transplant 24.0  11.8 years), and 63% of
these patients were known to be alive at last follow-up.
ABNORMALITIES RELATEDTOFONTANPHYSIOLOGY. The
overall incidence of PLE in this study was 9%, which
is similar to the 5% to 15% incidence quoted in other
large studies (23–25). Freedom from developing PLE
at 10, 20, and 30 years post-Fontan procedure was
92%, 89%, and 83%, respectively. Survival at 5, 10,
and 20 years after diagnosis of PLE was 50%, 35%, and
19%, respectively. As noted in previous studies,
elevated pre-operative mean PAP and post-bypass LA
pressure were associated with an increased risk of
developing PLE (23). A contemporary cohort of pa-
tients with PLE followed at our institution had much
better survival (25); however, this study included
patients who did not have their Fontan operations at
our institution. Hence, it is not a cohort study, and
one cannot directly compare those survival statistics
with those of a cohort study such as ours. Nonethe-
less, the substantial mortality in our cohort would
suggest that aggressive management of PLE and
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A
B
Although the Fontan procedure has improved overall survival in patients with single ventricles, various events impact long-term survival,
including diagnosis of protein-losing enteropathy (A). Other factors that adversely affect survival are pre-operative diuretic use, longer
cardiopulmonary bypass time, timing of surgery, simultaneous atrioventricular valve replacement, and post-operative ventricular arrhythmias.
Post-operatively, 82% of patients responding (n ¼ 305 surveys) rated their current health status as good or excellent (B).
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Over the last 40
years, surgical techniques used in the Fontan operation have
evolved and survival rates have improved, but post-operative
protein-losing enteropathy and arrhythmias and the need for reop-
eration during long-term follow-up remain considerable challenges.
TRANSLATIONAL OUTLOOK: Further long-term studies are
needed to examine the occurrence of late complications in pa-
tients who have undergone atriopulmonary Fontan procedures.
FIGURE 4 Pre- and Post-Operative Physical Status
85%
6%
9%
Improved
No change
Worse
The Fontan operation improved physical status in 85% of
patients (n ¼ 284 surveys).
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1709earlier consideration of heart transplant might be
important in these patients, especially if the PLE is
refractory to medical management.
Overall, 44% of patients had a diagnosis of a
new clinical arrhythmia during long-term follow-up.
Freedom from arrhythmia at 10, 20, and 30 years after
the Fontan operation was 71%, 42%, and 24%,
respectively. A majority of these patients had atrial
ﬂutter or ﬁbrillation, and a smaller proportion had re-
entrant supraventricular tachycardia, atrial tachy-
cardia, or ventricular tachycardia.
Increased attention is being paid to the develop-
ment of cirrhosis and hepatocellular carcinoma in
patients who have had the Fontan operation (26–32).
Presumably, this results at least in part due to
elevated hepatic venous pressure, but understanding
of the pathophysiology of liver dysfunction after
Fontan procedure is evolving. There is likely a strong
referral bias accounting for the high incidence of
cirrhosis in our patient cohort. However, it still
highlights the need for more aggressive evaluation
and management of liver disease in these patients.
The role of cardiac transplant (with or without
concomitant liver transplant) continues to be debated
in these patients (21,33–40).
QUALITY OF LIFE. Eighty percent of the patients af-
ter the Fontan operation rated their current health as
excellent, and a similar percentage of patients
thought that their physical status was improved.
There is likely a selection bias in these data because
the patients who chose to complete these surveys
may be healthier than their counterparts and had
their Fontan surgery during a later era. However, this
is consistent with previously reported data suggest-
ing that patients tend to perceive themselves ashaving a higher functional status compared with
control populations (41).
STUDY LIMITATIONS. One limitation of our study is
that it was a single-center cohort from a large tertiary
referral center over an almost 4-decade time frame.
Therefore, in all the late follow-up outcomes, the data
curves were censured using the date of last available
follow-up on each patient. Some of these results may
not be directly translatable to a younger cohort of
patients in a recent surgical era. Liver disease may be
underreported in this cohort because imaging studies
were not routinely performed in patients operated on
in the early surgical era. However, as more patients
with congenital heart disease live into adulthood,
these data are relevant in the medical management of
patients with atriopulmonary or lateral tunnel Fontan
operations, especially those who have survived 20 to
30 years after their initial operation.
CONCLUSIONS
With better patient selection and evolution of surgical
techniques and medical management of patients after
the Fontan operation, there has been improvement in
survival over the last 40 years. The overall 10-, 20-,
and 30-year survival in our study from the time of
operation was 74%, 61%, and 43%, respectively.
However, the development of PLE, ventricular fail-
ure, cirrhosis, arrhythmias, and the need for reoper-
ation during long-term follow-up pose signiﬁcant
management challenges.
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